Broadway Advisor Group
    Wealth Planning for Regeneron Scientists & Biotech Professionals

    For Regeneron & Biotech Professionals

    Wealth Planning for Regeneron Scientists & Biotech Professionals

    Concentrated REGN equity, complex deferred compensation, and a biotech career that demands long-term thinking. Your wealth deserves the same.

    Regeneron's growth has built real wealth for the scientists, engineers, and managers who powered it — and that wealth comes with planning challenges most national advisors are not equipped to handle. Concentrated REGN positions, performance-based RSU vesting, deferred compensation elections, and the cyclical volatility of biotech equity all demand a measured, tax-aware approach. We work with biotech professionals throughout the Capital Region and Hudson Valley to convert paper wealth into family wealth — without leaving money on the table.

    01

    REGN concentration management

    When 40, 60, or 80% of your net worth is in one ticker, the planning question is not 'will Regeneron do well' — it's 'what's the cost of being wrong.' We build disciplined diversification programs that respect tax efficiency and your conviction in the company.

    02

    Equity-comp tax engineering

    RSU vesting, performance-share units, ESPP enrollment, and stock-option exercise timing each create distinct tax events. We coordinate them with the rest of your income picture to minimize unnecessary tax drag.

    03

    Long-horizon biotech wealth

    Biotech careers can include sabbatical years, equity windfalls, and periods of intense work followed by extended decompression. We plan around the cadence of your life, not around generic retirement-at-65 templates.

    What's included

    • REGN concentration analysis and diversification roadmap
    • 10b5-1 plan coordination with your trading window
    • RSU vest-and-sell programs with tax-aware tranching
    • ESPP enrollment optimization and disqualifying-disposition modeling
    • ISO/NSO exercise modeling with AMT impact analysis
    • Deferred compensation election strategy
    • Asset-location planning across taxable, IRA, and 401(k) accounts
    • Backdoor and mega-backdoor Roth implementation
    • Coordination with Tarrytown / Hudson Valley estate counsel
    • In-person reviews at our Albany office or secure video

    Concentration is the silent risk

    We've worked with biotech professionals through every kind of cycle. The single most common, most damaging mistake we see is letting concentrated company stock build to a level where a single bad clinical readout, a regulatory delay, or a sector-wide repricing can permanently impair the family's financial future. The discipline of trimming systematically — through pre-set rules, 10b5-1 plans, and clearly defined concentration thresholds — is the difference between turning equity comp into wealth and watching it evaporate.

    Frequently Asked

    Questions we often hear

    Belief in the company and concentration risk are two different conversations. Plenty of brilliant scientists and managers have watched concentrated positions in great companies lose 50–80% of their value during a single downturn. Diversification doesn't require betting against your employer — it requires recognizing that your salary, your bonus, your equity comp, and your largest investment holding are all tied to the same business. Diversifying the investment leg lets you stay fully committed to your career while protecting your family.

    Begin a Conversation

    Schedule a private consultation at our Albany office or by video.

    Schedule Consultation